Fig. 2: PIAS2b-dsRNAi deleterious action in growth is rescued by PIAS2b SUMOylation activity. Commercial PIAS2b siPOOL reproduces the effect with less potency. | Nature Communications

Fig. 2: PIAS2b-dsRNAi deleterious action in growth is rescued by PIAS2b SUMOylation activity. Commercial PIAS2b siPOOL reproduces the effect with less potency.

From: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

Fig. 2

a, b Inhibitory effect of PIAS2b-dsRNAi 1 in 8305C cells is rescued by FLAG-PIAS2b or EGFP-PIAS2b, but not by FLAG-PIAS2a, FLAG-PIAS2b-C362A or EGFP-PIAS2b-C362A point mutant (PIAS2b SUMO-DEAD) cDNA transfection. As shown above, PIAS2b-dsRNAi is designed at the 3′ UTR not present in the expression plasmid. c Commercial siPOOL against all PIAS2 isoforms is not effective reducing protein or cell growth in 8305C cells. Custom-ordered siPOOL targeting PIAS2b specifically (similar isoforms as PIAS2b-dsRNAi) reduces protein expression and cell growth, although less efficiently than PIAS2b-dsRNAi at Day 6. d Western blots comparing both treatments at day 2 and 3 post-transfection show delayed protein suppression by PIAS2b siPOOL. a n = 8 independent experiments; b, c n = 3 independent experiments; d n = 2 independent experiments. a–c Two-sided one-way ANOVA. Bar indicate means ± SEM; when significant the exact p value is indicated in the figure. Source data are provided as a Source Data file.

Back to article page